🧠 Food for thought

Implications, context, and why it matters.

Europe’s uneven blood testing rules slow Lucis

• Lucis works in France and the UK. It also runs services in Ireland and Portugal. The EU’s In Vitro Diagnostic Regulation (IVDR) covers in vitro diagnostic (IVD) devices such as test kits but not testing services, which leaves member states with uneven oversight 1.
• In the UK, direct-to-consumer testing has notable gaps. Only 27% of self-test boxes list who should use them at the point of sale, and for 58% of conditions the marketed intended use conflicts with evidence-based guidance 2. These quality issues will slow any standard rollout.
• Rules differ on doctor orders, promotion of results, and follow-up. Some states require a post-result medical consult. Cross-border online sales make enforcement harder 1, so Lucis must follow national rulebooks across Europe.

Labs and logistics lag as preventive testing grows

• Lucis has run 500,000+ tests across four countries. That volume signals demand for mobile phlebotomy and specimen logistics across Europe. Current phlebotomy and courier providers stay fragmented. Platforms can standardize collection, chain-of-custody tracking (an auditable trail for handling samples), and lab links 3.
• The laboratory information system (LIS) market is $891 million in 2024 and could reach $1.3 billion by 2032 4. That creates room for software between consumer apps and certified labs to connect across borders.
• Investors see a move toward “systems of action”, software that turns insights into automated workflows, built with AI-first designs 4. Data tools can help preventive platforms like Lucis turn results into actions and stay compliant by country.